The researchers profiled 92 clinically available kinase inhibitors against 409 wild type kinases and 349 cancer-associated kinase variants using a kinase activity assay that quantifies the transfer of radiolabeled phosphate groups from ATP to relevant protein targets in the presence and absence of inhibitors. Of the 349 cancer-associated variants studied, 140 have been identified in rare cancers, including 55 variants identified exclusively in rare cancers. Dr. Marina Chan, a Senior Staff Scientist and co-senior author of the study, highlighted the relevance to rare cancers: “Rare cancers often harbor uncommon kinase mutations for which there are no specifically developed therapies. By systematically testing these variants against drugs that are already available, we can identify treatment opportunities that might otherwise be missed.”
The screen revealed that the panel of existing drugs inhibited 235 wild type kinases, a substantial increase from the 89 already established. Additionally, the drugs inhibited 94% of the oncogenic kinase mutants. Dr. Gujral commented, “We found that the therapeutic reach of these drugs is much broader than previously appreciated. Importantly, many cancer-associated kinase mutations could potentially be targeted by drugs that already exist.”
The team explored several opportunities for repurposing existing kinase inhibitors for new targets. The inhibitor profiling showed that tepotinib, developed to target the kinase MET, also inhibits the activity of IRAK1 and IRAK4, two related kinases implicated in various solid tumor cancers and inflammatory diseases. In cell models of glioblastoma, a difficult-to-treat brain cancer where high IRAK1/4 abundance associates with poor survival, treatment with tepotinib led to reduced cell growth, as well as downregulation of genes involved in tumor growth and survival. Consistent with these results, tepotinib significantly reduced the growth of IRAK1/4 expressing glioblastoma tumors in a patient-derived xenograft mouse model, supporting further investigation of tepotinib as a potential strategy for IRAK1/4-high glioblastoma.
The kinase inhibitor screen revealed therapeutic gaps for several cancers involving kinase mutants. For example, mutations in the kinases FGFR and MET occur across multiple solid tumors, including in lung cancer. However, the kinase inhibitors generally clinically approved for lung cancer failed to inhibit six FGFR and four MET kinase mutants. The inhibitor screen identified selpercatinib, currently approved specifically for RET fusion positive non-small cell lung cancer and thyroid cancer, as an effective inhibitor across FGFR mutant variants. Gilteritinib, approved for acute myeloid leukemia with a mutation in the FLT3 kinase, inhibited the four MET mutant variants. These inhibitors may be promising drugs for FGFR and MET mutant variant-associated cancer across the multiple solid tumor types where they occur.
The dataset from the study revealed many additional opportunities for drug repurposing. The researchers built a web-based tool, Kinase Inhibitor Repurposing Hub (KIRHUb), that makes the inhibitor screen data accessible for other researchers and clinicians to explore and build upon. The hope is that this is the first step toward embracing polypharmacology and guiding precision medicine for kinase inhibitor treatments.
This work also aligns with the mission of TRACER (Transformative Rare Cancer Initiative), led by Dr. Gujral, which aims to identify and accelerate new therapeutic opportunities for patients with rare cancers. Moving forward, Dr. Gujral and his team “are particularly excited about applying this approach to rare cancers, where there are often few disease-specific therapies and developing a new drug for every rare cancer is simply not practical. Being able to connect an actionable kinase dependency with an existing drug could open up treatment opportunities that otherwise might be missed.”